Cybin Inc. Achieves Breakthroughs in Mental Health Treatment

Cybin ( (TSE:CYBN) ) has issued an update.

Cybin Inc. announced significant achievements in 2024, including successful Phase 2 results for its CYB003 drug, demonstrating a breakthrough in treating major depressive disorder. The company received FDA Breakthrough Therapy Designation for CYB003 and initiated a multinational pivotal Phase 3 program. Looking forward to 2025, Cybin anticipates advancing its clinical pipeline with key milestones, including topline efficacy data for CYB004 in generalized anxiety disorder and further progress in its Phase 3 program.

More about Cybin

Cybin Inc. is a clinical-stage neuropsychiatry company focused on developing innovative next-generation treatment options for mental health conditions. The company specializes in creating tryptamine serotonin receptor agonists, such as CYB003 and CYB004, designed for treating major depressive disorder and generalized anxiety disorder, respectively.

YTD Price Performance: -5.53%

Average Trading Volume: 350,407

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $1.36M

Learn more about CYBN stock on TipRanks’ Stock Analysis page.